විකිපීඩියා

සැකිල්ල:Infobox drug/testcases2

< සැකිල්ල:Infobox drug
Current test: Licence, title

CompTox (EPA)

සංස්කරණය
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
Riboflavin
Chemical structure
Clinical data
Trade namesMany[1]
Other nameslactochrome, lactoflavin, vitamin G
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth, intramuscular, intravenous
ATC code
Legal status
Legal status
  • US: Dietary supplement
Pharmacokinetic data
Elimination half-life66 to 84 minutes
ExcretionUrine
Identifiers
  • 7,8-Dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H20N4O6
Molar mass376.37 g·mol−1
3D model (JSmol)
  • c12cc(C)c(C)cc1N=C3C(=O)NC(=O)N=C3N2C[C@H](O)[C@H](O)[C@H](O)CO
  • InChI=InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1 YesY
  • Key:AUNGANRZJHBGPY-SCRDCRAPSA-N YesY
Riboflavin
Chemical structure
Clinical data
Trade namesMany[1]
Other nameslactochrome, lactoflavin, vitamin G
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth, intramuscular, intravenous
ATC code
Legal status
Legal status
  • US: Dietary supplement
Pharmacokinetic data
Elimination half-life66 to 84 minutes
ExcretionUrine
Identifiers
  • 7,8-Dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H20N4O6
Molar mass376.37 g·mol−1
3D model (JSmol)
  • c12cc(C)c(C)cc1N=C3C(=O)NC(=O)N=C3N2C[C@H](O)[C@H](O)[C@H](O)CO
  • InChI=InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1 YesY
  • Key:AUNGANRZJHBGPY-SCRDCRAPSA-N YesY

Licence

සංස්කරණය
සංස්කරණය
{{Infobox drug}}
{{Infobox drug/licence}}
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
Infobox drug/testcases2
INN: Linezolid
Infobox drug/testcases2
INN: Linezolid

test1

සංස්කරණය
Tegafur/gimeracil/oteracil (~random)
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
Infobox drug/testcases2
Combination of
TegafurAntineoplastic drug
GimeracilEnzyme inhibitor
OteracilEnzyme inhibitor
Clinical data
Trade namesTeysuno, TS-1
Other namesS-1[3]
AHFS/Drugs.comUK Drug Information
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)[2]
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
Infobox drug/testcases2
Combination of
TegafurAntineoplastic drug
GimeracilEnzyme inhibitor
OteracilEnzyme inhibitor
Clinical data
Trade namesTeysuno, TS-1
Other namesS-1[3]
AHFS/Drugs.comUK Drug Information
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)[2]
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID

licence CA

සංස්කරණය

add licence_CA

සංස්කරණය

විරේචනය

Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
Infobox drug/testcases2
INN: Linezolid
Skeletal formula of linezolid
Clinical data
Pronunciation/njuːˈməʊniə/
Trade namesLinospan, Zyvox, Zyvoxam, Zyvoxid
Other namesLenzomore
AHFS/Drugs.comMonograph
MedlinePlusa602004
License data
Pregnancy
category
  • AU: C
Dependence
liability		High
Addiction
liability		Low
Routes of
administration		Intravenous infusion, oral
ATC code
Pharmacokinetic data
Bioavailability~100% (oral)
Protein bindingLow (31%)
MetabolismHepatic (50–70%, CYP not involved)
Metabolitessome stuff
Onset of action1 hr
Elimination half-life4.2–5.4 hours (shorter in children)
Duration of action1 to 3 hr
ExcretionNonrenal, renal, and fecal
Identifiers
  • (S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
PDB ligand
Chemical and physical data
FormulaC16H20FN3O4
Molar mass337.346 g/mol
3D model (JSmol)
Density1.40 g/cm3
Melting point135 °C (275 °F)
Boiling point140 °C (284 °F) (decomposes)
Solubility in water3 mg/mL (20 °C)
  • O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
  • InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 YesY
  • Key:TYZROVQLWOKYKF-ZDUSSCGKSA-N YesY
 ☒NYesY (what is this?)  (verify)
Infobox drug/testcases2
INN: Linezolid
Skeletal formula of linezolid
Clinical data
Pronunciation/njuːˈməʊniə/
Trade namesLinospan, Zyvox, Zyvoxam, Zyvoxid
Other namesLenzomore
AHFS/Drugs.comMonograph
MedlinePlusa602004
License data
Pregnancy
category
  • AU: C
Dependence
liability		High
Addiction
liability		Low
Routes of
administration		Intravenous infusion, oral
ATC code
Pharmacokinetic data
Bioavailability~100% (oral)
Protein bindingLow (31%)
MetabolismHepatic (50–70%, CYP not involved)
Metabolitessome stuff
Onset of action1 hr
Elimination half-life4.2–5.4 hours (shorter in children)
Duration of action1 to 3 hr
ExcretionNonrenal, renal, and fecal
Identifiers
  • (S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
PDB ligand
Chemical and physical data
FormulaC16H20FN3O4
Molar mass337.346 g/mol
3D model (JSmol)
Density1.40 g/cm3
Melting point135 °C (275 °F)
Boiling point140 °C (284 °F) (decomposes)
Solubility in water3 mg/mL (20 °C)
  • O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
  • InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 YesY
  • Key:TYZROVQLWOKYKF-ZDUSSCGKSA-N YesY
 ☒NYesY (what is this?)  (verify)

විරේචනය

English language variants: Licence or License

සංස්කරණය
See also WP:ENGVAR: english language variant of the article
In {{Infobox drug}}: spelling of licence/license. Default is to be en-US: License.
Use parameter |engvar= for non-default spelling:
Default licenSe (US)
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
demo
Clinical data
License data
demo
Clinical data
License data
|engvar=en-US licenSe
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
demo
Clinical data
License data
demo
Clinical data
License data
|engvar=en-UK licenCe
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
demo
Clinical data
Licence data
demo
Clinical data
Licence data
|engvar=en-NZ licenCe
Side by side comparison
{{Infobox drug}}{{Infobox drug/sandbox}}
demo
Clinical data
Licence data
demo
Clinical data
Licence data

NOWIKI FOR SPEED (July 2021)

සංස්කරණය

==Titletests (default, INN, drug_name)== ===Lysergide (LSD)=== {{Purge}} Reduced infobox. :Current infobox title: {{strong|1=Lysergic acid diethylamide}} (pagename, not INN) :New situation would be (adding "(LSD)" is just a liberty I took, to help our readers): {{Testcase table | drug_name=Lysergic acid diethylamide (LSD) | INN = Lysergide | IUPAC_name = (6a''R'',9''R'')-''N'',''N''-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-''fg'']quinoline-9-carboxamide | image = LSD-2D-skeletal-formula-and-3D-models.png <!--Clinical data--> | pregnancy_US = C | legal_AU = Schedule 9 | legal_CA = Schedule III | legal_NZ = Class A | legal_UK = Class A | legal_UN = P I | legal_US = Schedule I | legal_DE = Anlage I | addiction_liability = None | dependency_liability = Low | routes_of_administration = [[Oral administration|Oral]], etc <!--Pharmacokinetic data--> | metabolism = Hepatic | elimination_half-life = 3–5 hours | excretion = [[Renal]] <!--Identifiers--> | CAS_number = 50-37-3 | ChEBI = 6605 | PubChem = 5761 | IUPHAR_ligand = 17 | DrugBank = DB04829 | ChemSpiderID = 5558 | UNII = 8NA5SWF92O | ChEMBL = 263881 | ATC_prefix = none <!--Chemical data--> | C=20 | H=25 | N=3 | O=1 | synonyms = Acid, LSD, lysergide }} === (regular)=== * [[alpha-Methyltryptamine]] : No need to use {{para|INN}}. Note the titletext (mousehover). {{Testcase table | IUPAC_name = 2-(1''H''-indol-3-yl)-1-methyl-ethylamine | image = AMT.svg | width = 150px | drug_name = α-Methyltryptamine <!--Clinical data--> | routes_of_administration = [[Mouth|Oral]] <!--Identifiers--> | CAS_number = 299-26-3 | ATC_prefix = none | ATC_suffix = <!--Chemical data--> | C=11 | H=14 | N=2 | synonyms = Indopan; IT-290, IT-403, U-14,164E, 3-IT }} ===Default Title=== {{testcase table | CAS_number = 1234-56-7 | trade_names=no dn }} {{testcase table | drug_name = | CAS_number = 1234-56-7 | trade_names=blank dn }} {{testcase table | drug_name = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm }} {{testcase table | drug_name = Aspirin | CAS_number = 1234-56-7 | trade_names=dn is diff }} ==Test INN== {{testcase table | CAS_number = 1234-56-7 | trade_names=no dn | INN = inn }} {{testcase table | drug_name = | CAS_number = 1234-56-7 | trade_names=blank dn | INN = inn }} {{testcase table | drug_name = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm | INN = inn }} {{testcase table | drug_name = Aspirin [[Main page|MP]] | CAS_number = 1234-56-7 | trade_names=dn is diff | INN = inn }} ;blanks {{testcase table | drug_name = | CAS_number = | trade_names= | INN = }} ===INN=none=== {{testcase table | CAS_number = 1234-56-7 | trade_names=no dn }} {{testcase table | drug_name = | CAS_number = 1234-56-7 | trade_names=blank dn }} {{testcase table | drug_name = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm }} {{testcase table | drug_name = Aspirin | CAS_number = 1234-56-7 | trade_names=dn is diff }} ===INN=some sense=== {{testcase table | CAS_number = 1234-56-7 | trade_names=no dn | INN = inn }} {{testcase table | drug_name = | CAS_number = 1234-56-7 | trade_names=blank dn | INN = inn }} {{testcase table | drug_name = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm | INN = inn }} {{testcase table | drug_name = Aspirin | CAS_number = 1234-56-7 | trade_names=dn is diff | INN = inn }} ===INN='none'=== {{testcase table | CAS_number = 1234-56-7 | trade_names=no dn | INN = none }} {{testcase table | drug_name = | CAS_number = 1234-56-7 | trade_names=blank dn | INN = none }} {{testcase table | drug_name = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm | INN = None }} {{testcase table | drug_name = Aspirin | CAS_number = 1234-56-7 | trade_names=dn is diff | INN = none }} ===INN eq=== {{testcase table | drug_name = Infobox drug/testcases8 | INN = Infobox drug/testcases8 | CAS_number = 1234-56-7 | trade_names = dn=pagenm }} ==All blank== {{testcase table | no_param_name=99 }} ==All up== {{purge}} {{Testcase table | type = IUPAC | drug_name = 1/IUPAC | captionLR = Cap LR | imageL = L1 barcelona.svg | imageR = Tabliczka_R1.svg | widthL = 70px | widthR = 90px | altL = alt-L | altR = alt-R | Watchedfields = 103 | imagename = 2 | image = Racemic amphetamine 2.svg | width = 175px | alt = an example image | image2 = D-Amphetamine-3D-balls.png | width2 = 150px | alt2 = another example image | caption = some images | IUPAC_name = 12 | trivial_name = some-name | target = 13 | vaccine_type = Toxoid | mab_type = F(ab')2 | source = xi/a | component1 = 17 | class1 = 18 | component2 = 19 | class2 = 20 | component3 = 21 | class3 = 22 | component4 = 23 | class4 = 24 | tradename = 25 | tradename_pronunciation = twenty-five | tradename_synonym = two dozen plus one | Drugs.com = 27 | MedlinePlus = 29 | licence_CA = 29.5 | licence_EU = 30 | licence_US = 31 | DailyMedID = 32 | pregnancy_AU = B3 | pregnancy_US = C | pregnancy_category = 35 | legal_AU = S4 | legal_CA = Schedule IV | legal_UK = POM | legal_US = Schedule III | legal_UN = N II III | legal_EU = Category 2 Precursor | legal_status = RX | dependency_liability = 43-1 | addiction_liability = 43-2 | routes_of_administration = 44 | bioavailability = 45 | protein_bound = 46 | metabolism = 47 | onset = 47.5 | elimination_half-life = 48 | excretion = 49 | CAS_number = 50 | CAS_number_Ref = 51 | CAS_supplemental = 52 | ATCvet = 53 | ATC_prefix = 54 | ATC_suffix = 55 | ATC_supplemental = 56 | PubChem = 57 | PubChemSubstance = 58 | IUPHAR_ligand = 59 | DrugBank = 60 | DrugBank_Ref = 101 | ChemSpiderID = 61 | ChemSpiderID_Ref = 62 | UNII = 63 | UNII_Ref = 64 | KEGG = 65 | KEGG_Ref = 66 | ChEBI = 67 | ChEBI_Ref = 68 | ChEMBL = 69 | ChEMBL_Ref = 70 | NIAID_ChemDB = 71 | synonyms = 72 | PDB_ligand = 73 | chemical_formula = | C = 1 | H = 2 | Ag = 3 | Al = 4 | As = 5 | Au = 6 | B = 7 | Bi = 8 | charge = -1 | molecular_weight = 75 | show_all=yes | smiles = 76 | StdInChI = 77 | StdInChI_comment = 78 | StdInChI_Ref = 79 | StdInChIKey = 80 | StdInChIKey_comment = 81 | StdInChIKey_Ref = 82 | density = 83 | melting_point = 84 | melting_high = 85 | melting_notes = 86 | boiling_point = 87 | boiling_high = 104 | boiling_notes = 88 | solubility = 89 | chirality = 106 | specific_rotation = 90 | sec_combustion = 91 | Verifiedfields = 92 | verifiedrevid = 93 }} {{purge}} (reduced infobox) :Current infobox title: {{strong|1= Diamorphine ({{abbr|INN|International Nonproprietary Name}})}} : The new situation required an edit. {{testcase table | drug_name = Heroin | INN = Diamorphine | IUPAC_name = (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate | image = Heroin - Heroine.svg | image2 = Heroin-from-xtal-horizontal-3D-balls.png <!--Clinical data--> | pronounce = {{IPAc-en|ˈ|h|ɛ|r|o:|ɪ|n}} | Drugs.com = {{drugs.com|parent|heroin}} | legal_AU = S9 | dependency_liability = Physical: Very high<br />Psychological: Very high | addiction_liability = Very high | routes_of_administration = Inhalation, transmucosal, intravenous, oral, intranasal, rectal, intramuscular <!--Identifiers--> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 561-27-3 | ATC_prefix = N07 | ATC_suffix = BC06 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 27808 | PubChem = 5462328 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB01452 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4575379 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 8H672SHT8E | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 459324 <!--Chemical data--> | C=21 | H=23 | N=1 | O=5 | molecular_weight = 369.41 g/mol | synonyms = Diamorphine, Diacetylmorphine, Acetomorphine, (Dual) Acetylated morphine, Morphine diacetate }}

  1. ^ "Riboflavin". Drugs.com. 22 July 2021. සම්ප්‍රවේශය 8 October 2021.
  2. ^ "Teysuno 20mg/5.8mg/15.8mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). සම්ප්‍රවේශය 30 July 2020.
  3. ^ Liu TW, Chen LT (201). "S-1 with leucovorin for gastric cancer: how far can it go?". Lancet Oncol. 17 (1): 12–4. doi:10.1016/S1470-2045(15)00478-7. PMID 26640038.
"https://si.wikipedia.org/w/index.php?title=සැකිල්ල:Infobox_drug/testcases2&oldid=682110" වෙතින් සම්ප්‍රවේශනය කෙරිණි